focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half Yearly Report

16 Dec 2008 07:00

RNS Number : 1756K
ViaLogy PLC
16 December 2008
 



ViaLogy PLC ("ViaLogy" or "the Company")

Interim Report and Unaudited accounts for six months ended 30 September 2008

Chairman's statement for the six months ended 30 September 2008

The Interim report covers the six-month period to 30 September 2008. The figures show a loss for the period of £2,597,102, which includes £1,176,605 for amortisation and depreciation. The amortisation charge relates to the value of ViaLogy's Intellectual Property and associated Research and Development, which is amortised over a total of six years. The cash outflow from operations during the period was £1,348,898.

In August 2008 ViaLogy raised £1.8 million by way of a placing of 45 million new ordinary shares at 4p per share. In addition, subject to shareholder approval which was subsequently given at the AGM, the placees received one warrant for every ordinary share purchased in the placing. Each warrant entitles the holder to purchase an additional ordinary share at 5p at any time up to 29 October 2011.

During the April - September months the Company made considerable technical progress particularly in the two sectors where it is focussing its principal commercial efforts, Safety & Security and Oil & Gas. 

In the Safety & Security sector we have been working in partnership with governments and international organisations including the US Department of Defence, Cisco and SAIC, to integrate ViaLogy's Sensor Policy Manager (SPM™) product into installations in the US and overseas. Such major contracts take a considerable time to negotiate and plan but we are confident that SPM ™ is on its way to becoming an element of these vital security systems. 

In September 2008 we analysed the seismic data for an exploratory oil well drilling in Texas with Atascosa Exploration. Using QRI, our location predictions proved completely accurate and in January 2009 we will embark on two further proof-of-concept drilling projects with Atascosa. We also made satisfactory progress in the adaptation of QRI for the precise geolocation of oil and gas pipelines. In October 2008 we carried out the first pipeline survey test flight with Sky Research, combining QRI with state-of-the-art synthetic aperture radar. We intend to demonstrate a new approach , and a pipeline survey product, that is cost-effective, robust, and meets pipeline industry criteria. 

Our work throughout 2008 has been carried out in an international financial and commercial environment that is the most difficult I have ever experienced. In such circumstances it is incumbent upon small companies such as ViaLogy, with a strong technology potential but yet to make its commercial mark, to be prudent in its financial planning. We have looked carefully at every aspect of our overhead expenditure and made cost savings wherever possible. In addition, directors and staff have agreed to make personal financial sacrifices to ensure the continued well-being of the Company and I thank them on behalf of the board and the shareholders.

Terry Bond

Chairman

ViaLogy PLC

16 December 2008

  

Chief Executive Officer's review

Oil & Gas

Working closely with San Antonio-based partner Atascosa Exploration LLP, ViaLogy has determined the location of an additional hydrocarbon reservoir, this one gas. Using QuantumRD, ViaLogy's proprietary technology for geoseismic analysis that assesses the location, capacity and payout of hydrocarbon reservoirs, Atascosa plans to complete drilling in January 2009. ViaLogy is also fixing the location of another oil reservoir for Atascosa, and determining the optimal drill location. Drilling on this second project should also be completed in the January/February 2009 timeframe. Success with these projects will give ViaLogy a 5% working interest in their output, and should mark a major milestone in proof-of-concept acceptance of the QuantumRD technology by the oil and gas exploration industry. ViaLogy intends to market its QuantumRD product aggressively, and to enter immediately into additional drilling projects with Atascosa. Atascosa CEO, John Mullins, said, "Our willingness to commit major development funding to the two wells speaks for itself with respect to our confidence in the QuantumRD technology."

ViaLogy has also made significant progress in productizing its core IP, Quantum Resonance Interferometry or QRI™, with its application to precisely geolocate buried oil and gas pipeline. This application of QRI™ is branded as QSUB™. QRI™ itself is a tool for the extraction of hard-to-find information from sensor data that frustrate other software processing techniques; it has wide applicability in that it can be applied to data from virtually any type of sensor. Precisely locating buried pipeline more cost effectively than current techniques is a business service for which there is a substantial market, and for which ViaLogy believes QSUB™ has a direct and cost-cutting utility. ViaLogy's work over the last six months has been to demonstrate a new approach that is dependable, robust, and meets pipeline industry criteria; we have not encountered any setback with the application of the QRI™ technology. We are pleased with our progress toward achieving an industry-accepted proof-of-concept, although a better-funded effort would accelerate progress. Working within ViaLogy's resource constraints, and using multiple synthetic aperture radar data sets to confront the technology with a demanding variety of soil conditions, ViaLogy is showing that QSUB™  can both locate otherwise impossible-to-find buried metal objects, and improve radar's performance by determining when it produces false alarms. This work translates directly into the pipeline application. We hope to be able to report major milestones in the first quarter of  2009 about carrying the pipeline business forward.

Safety & Security

In the Physical Security Information Management market, ViaLogy's flagship security software product SPM™ (Sensor Policy Manager™) has made major steps forward in the face of economic and business challenges in the security software business stemming from difficulties in the wider economy. Our Canadian partner Axia Supernet has decided to expand a joint SPM™ air quality monitoring operational pilot as a step toward winning customer acceptance of a province-wide deployment. SPM™ is operating in Los Angeles County as the core piece of a chemical toxin early warning system sponsored by the [US Department of Health & Safety] and the Company expects this system to be expanded in LA County and further deployed to other major US cities. In cooperation with a major US defense contractor, ViaLogy has successfully integrated multiple perimeter surveillance radars into an Air Force Asian base security system and ViaLogy expects further orders for other bases; SPM™ is also being evaluated for supporting US Army base security systems. In addition, one of  ViaLogy's partners, Cisco Systems Inc, has put in place a targeted marketing effort for its COPSS integrated security solution; SPM™ is an integral part of COPSS and Cisco systems Inc and ViaLogy are jointly approaching major potential customers. In summary, the Company has a growing sales pipeline for its SPM™ and looks toward substantial income in 2009.

Outlook

ViaLogy looks back on a year of achievement in presenting its technologies as products that will introduce efficiencies in the energy and security markets. We expect significant expansion of our revenues from operations as the new year progresses.

Robert W. Dean

Chief Executive Officer

ViaLogy PLC

16 December 2008

Consolidated income statement for the six months ended 30 September 2008

Unaudited

Unaudited

Audited

6 months

6 months

Year to 

to 30 Sep 

to 30 Sep 

to 31 Mar 

Notes

2008

2007

2008

£

£

£

Revenue

32,444

22,567

31,485

Cost of sales

10,587

408

407

--------

--------

--------

Gross profit

21,857

22,159

31,078

Administrative expenses 

2,853,184

2,266,459

5,409,444

--------

--------

--------

Loss from Operations

(2,831,327)

(2,244,300)

(5,378,366)

Finance costs

-

(1,275)

-

Finance income

32,128

52,776

119,985

--------

--------

--------

Loss for the year before  taxation 

(2,799,199)

(2,192,799)

(5,258,381)

--------

--------

--------

Taxation

202,097

195,143

389,454

--------

--------

--------

Loss for the year attributable to equity 

holders of the parent

(2,597,102)

(1,997,656)

(4,868,927)

--------

--------

--------

£

£

£

Loss per share

Basic  and diluted

(0.55)p

(0.46)p

(1.091)p

Consolidated statement of changes in equity for the six months ended 30 September 2008

Share

Share 

Warrant

Foreign

Retained

Total

capital

premium

reserve

exchange

earnings

account

reserve

At 1 April 2008

4,587,736

14,511,702

275,000

(436,394)

(8,437,103)

10,500,941

Loss for period

-

-

-

-

(2,597,102)

(2,597,102)

Exchange differences arising on 

translation of foreign operations

-

-

-

764,504

-

764,504

--------

--------

--------

--------

--------

--------

Total income and expense 

-

-

-

764,504

(2,597,102)

(1,832,598)

recognised for the year

Arising on issue of shares

450,000

1,186,500

-

-

-

1,636,500

Arising on issue of  warrants

-

-

112,500

-

-

112,500

Share options expense

-

-

-

-

338,685

338,685

--------

--------

--------

--------

--------

--------

Balance at 30 September 2008

5,037,736

15,698,202

387,500

328,110

(10,695,520)

10,756,028

--------

--------

--------

--------

--------

--------

Consolidated balance sheet at 30 September 2008

Unaudited

Unaudited

Audited

Notes

30 Sep 

30 Sep 

31 Mar 

2008

2007

2008

£

£

£

Assets

Non current assets

Property, plant and equipment

149,995

86,558

99,343

Intangible Assets

10,456,844

10,390,570

10,148,333

Financial Assets

200,000

200,000

200,000

--------

--------

--------

10,677,128

10,447,676

--------

--------

--------

Current assets

Inventories

12,469

7,363

10,515

Trade and other receivables 

49,272

45,879

29,116

Cash and cash equivalents

1,961,491

3,983,337

2,190,050

--------

--------

--------

4,036,579

2,229,681

--------

--------

--------

Total Assets

12,830,071

14,713,707

12,677,357

--------

--------

--------

Liabilities

Current liabilities

Trade and other payables

317,451

211,368

380,246

Non-current liabilities

Deferred tax liability

1,756,592

1,940,944

1,796,170

--------

--------

--------

Total liabilities

2,074,043

2,152,312

2,176,416

Capital and reserves attributable to equity

holders of the Company

 Share capital

5,037,736

4,587,158

4,587,736

 Share premium account

15,698,202

14,481,849

14,511,702

Warrant Reserve

387,500

275,000

275,000

 Foreign Exchange translation reserve

328,110

(656,772)

(436,394)

 Retained Earnings

(10,695,520)

(6,125,840)

(8,437,103)

--------

--------

--------

Shareholders' funds

12,561,395

10,500,941

--------

--------

--------

Total equity and liabilities

12,830,071

14,713,707

12,677,357

--------

--------

--------

Consolidated cash flow statement for six months ended 30 September 2008

Unaudited

Unaudited

Audited

30 Sep 

30 Sep 

31 Mar 

2008

2007

2008

£

£

£

Operating Activities

Loss  before tax

(2,799,199)

(2,192,799)

(5,258,381)

Adjustments for :-

Finance income

(32,128)

(52,776)

(119,985)

Finance cost

-

1,275

-

Depreciation

27,025

15,689

43,623

Amortisation

1,176,605

1,040,359

2,181,438

Share option expense

338,685

217,133

806,994

Foreign exchange movements

(7,109)

(3,901)

(4,076)

--------

--------

--------

Operating Activities before changes in working capital

(1,296,121)

(975,020)

(2,350,387)

Reduction/(Increase) in trade and other receivables

(20,156)

(2,547)

14,216

Increase in inventories

(1,954)

(5,398)

(8,550)

(Reduction)/Increase in trade and other payables

(62,795)

41,673

210,551

Interest received

32,128

52,776

119,985

Interest paid

-

(1,275)

-

--------

--------

--------

Cash generated from operations

(1,348,898)

(889,791)

(2,014,185)

Investing activities

 Internally generated intangible asset

(535,255)

(615,626)

(1,245,207)

 Acquisition of tangible fixed assets

(93,406)

(51,346)

(91,236)

--------

--------

--------

(1,977,559)

(1,556,763)

(3,350,628)

Financing Activities

Cash inflow from issue of new shares (net of 

issuance costs)

1,749,000

4,315,680

4,342,823

 Cash inflow from exercise of options

-

26,565

-

--------

--------

--------

Decrease in cash and cash equivalents

(228,559)

2,785,482

992,195

Cash and cash equivalents at beginning of year

2,190,050

1,197,855

1,197,855

--------

--------

--------

Cash and cash equivalents at end of year

1,961,491

3,983,337

2,190,050

--------

--------

--------

Notes forming part of the parent company financial statements

1.
Accounting policies

Basis of preparation

The financial information has been prepared in accordance with International Financial Reporting Standards (IFRS) and stated in British pounds (£). In preparing the interim financial statements, the same accounting policies are applied as in the preparation of the audited Financial Statements for the year ended 31 March 2008 except for the changes set out below.

The above financial information does not constitute statutory accounts within the meaning of Section 240, Companies Act 1985. The information relating to the six months ended 30 September 2008 has been reviewed but not audited. Information relating to the year ended 31 March 2008 has been extracted from the statutory accounts of the Group which have been audited by the Group's auditors BDO Stoy Hayward and whose report thereon is unqualified. 

Going concern

The Group's financial plans require the Group to secure a number of sales contracts over the course of the coming year in order to fund the working capital requirements and the development programme of the Company and Group. The majority of these sales contracts have not yet been secured and although the Board believes that these contracts will be secured this constitutes a significant uncertainty. In the event that these sales contracts are not received in line with the Group's financial plans then Directors are confident that further equity funding could be raised or expenditure could be sufficiently reduced to ensure that funds are available to meet working capital requirements. Accordingly the Group's financial statements have been prepared on a going concern basis.

2.
Segmental Analysis

The Group's primary and secondary formats for reporting segment information are shown below. The primary operations segment is based in the USA; the head office primary segment is based in the UK. The differing geographical locations being the secondary segment overlap completely with the differing nature of the business segments.

2008 Business Segments

Operations

Head Office

Unallocated

Consolidated

£

£

£

£

Revenue

32,444

-

-

32,444

--------

--------

--------

--------

Gross profit

21,857

-

-

21,857

Net finance income

-

-

32,128

32,128

Net tax credit

-

-

202,097

202,097

Net loss for the period

(2,272,618)

(558,709)

234,225

(2,597,102)

Segment assets

8,937,308

2,136,171

1,756,592

12,830,071

Segment liabilities

230,301

87,150

1,756,592

2,074,043

--------

--------

--------

--------

Costs to acquire plant property and equipment

93,406

-

-

93,406

Costs to acquire intangible assets

535,255

-

-

535,255

Depreciation and amortisation

1,202,974

656

-

1,203,630

Share based payments charged

338,685

338,685

--------

--------

--------

--------

All sales were to external customers.

2007 Business Segments

Operations

Head Office

Unallocated

Consolidated

£

£

£

£

Revenue

22,567

-

-

22,567

--------

--------

--------

--------

Gross profit

22,159

-

-

22,159

Net finance income

-

-

52,776

52,776

Net tax credit

-

-

195,143

195,143

Net loss for the period

(1,894,703)

(546,015)

247,919

(2,192,799)

Segment assets

4,609,529

4,126,655

1,940,944

10,677,128

Segment liabilities

67,283

144,085

1,940,944

2,152,312

--------

--------

--------

--------

Costs to acquire plant property and equipment

50,530

816

-

51,346

Costs to acquire intangible assets

615,626

-

-

615,626

Depreciation and amortisation

1,055,489

559

-

1,056,048

Share based payments charged

-

217,133

-

217,133

--------

--------

--------

--------

All sales were to external customers.

3.
Taxation on profits from ordinary activities

The movement on the tax account relates to the release of the provision on the deferred tax credit. The calculation is shown below: 

2008

2007

£

£

At 1 April

1,908,970

2,298,425

Release for the six months to 30 Sept 2008

(202,094)

(195,143)

Foreign exchange translation

49,716

(162,312)

--------

--------

At 30 September 

1,756,592

1,940,963

--------

--------

Deferred tax is calculated in full on temporary differences under the liability method using a tax rate of 35%.

4.
Loss per share

Basic

The calculation of earnings per share is based on the loss for the period of £2,597,102 (2006 - loss £1,997,656 ) and on 503,125,537 (2006 - 434,204,404) ordinary shares, being the weighted average number of ordinary shares in issue during the period.

Diluted

Diluted earnings per share dilute the basic earnings per share to take into account share options and warrants. The calculation includes the weighted average number of ordinary shares that would have been issued on the conversion of all the dilutive share operations and warrants into ordinary shares. 64,830,702 options and 76,193,654 warrants have been excluded from this calculation as this would reduce the loss per share.

Share capital

Authorised

2008

2007

2008

2007

Authorised

2008

2007

2008

2007

Number

Number

£

£

Ordinary Shares of 1p Each

750,000,000

750,000,000

7,500,000

750,000,000

__________

__________

__________

__________

Allotted, called up and fully paid 

2008

2007

2008

2007

Allotted, called up and fully paid 

2008

2007

2008

2007

Number

Number

£

£

Ordinary Shares of 1p Each

At 1 April

458,773,621

403,125,537

4,587,736

4,031,255

Shares issued for cash 

45,000,000

55,000,000

450,000

550,000

Employee Share option exercised

-

590,334

-

59,033

At 30 September

503,773,621

458,715,871

5,037,736

4,587,158

__________

__________

__________

__________

On 19 August 2008 the Company issued 45,000,000 shares of 1p each at 4p per share by way of a private placing.

5.
Reserves

2008

Ordinary share

 capital

Share 

Premium account

Warrant

Scheme 

reserve

Foreign Exchange 

Retained

earnings 

£

£

£

£

£

At 1 April 2008

4,587,736

14,511,702

275,000

(436,394)

(8,437,103)

Arising on issue of Shares 

450,000

1,237,500

112,500

-

-

Fundraising costs

-

(51,000)

-

-

-

Loss for the period

-

-

-

-

(2,597,102)

Arising in the period

-

-

-

764,504

-

Share option expense

-

-

-

-

338,685

--------

--------

--------

-------

--------

At 30 September 2008

5,037,736

15,698,202

387,500

328,110

(10,695,520)

_________

_________

_________

_________

_________

2007

Ordinary share

 capital

Share 

Premium account

Warrant

Scheme 

reserve

Foreign Exchange 

Retained

earnings 

£

£

£

£

£

At 1 April 2007

4,031,255

10,970,508

-

20,075

(4,345,317)

Arising on issue of Shares 

555,903

3,595,661

275,000

-

-

Fundraising costs

-

(84,320)

-

-

-

Loss for the period

-

-

-

-

(1,997,656)

Arising in the period

-

-

-

(676,847)

-

Share option expense

-

-

-

-

217,133

--------

--------

--------

-------

--------

At 30 September 2007

4,587,158

14,481,849

275,000

(656,772)

(6,125,840)

_________

_________

_________

_________

_________

 

The following describes the nature and purpose of each reserve within shareholders equity:

Reserve Description and purposes

Share premium account Amount subscribed for share capital in excess of nominal

value.

Retained earnings Cumulative net gains and losses recognised in the 

consolidated income statement.

Foreign Exchange  Exchange difference arising on translation of foreign operations.

For further information please contact:

ViaLogy

Robert W. Dean, President and CEO - US. +1 626-296-6337

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734

Nominated Adviser (Seymour Pierce)

Mark Percy +44 (0) 207-107-8000

Brokers

St. Helens Capital +44 (0) 207-628-5582

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR EAKASFLDPFFE
Date   Source Headline
11th Sep 20237:00 amRNSCancellation - Yourgene Health plc
11th Sep 20237:00 amRNSDe-listing and cancellation of trading of Shares
8th Sep 202312:00 pmRNSForm 8.5 (EPT/RI) - Yourgene Health plc
8th Sep 202311:23 amRNSScheme of Arrangement becomes Effective
8th Sep 20239:54 amRNSForm 8.5 (EPT/RI)
8th Sep 20237:30 amRNSSuspension - Yourgene Health Plc
7th Sep 202311:46 amRNSCourt sanction of the Scheme of Arrangement
7th Sep 202310:10 amRNSForm 8.5 (EPT/RI)
5th Sep 202310:30 amRNSForm 8.5 (EPT/RI)
4th Sep 202310:01 amRNSForm 8.5 (EPT/RI)
1st Sep 20235:30 pmRNSYourgene Health
1st Sep 202312:07 pmRNSForm 8.5 (EPT/RI)
31st Aug 202310:58 amRNSForm 8.3 - Yourgene Health PLC
31st Aug 20239:42 amRNSForm 8.5 (EPT/RI)
30th Aug 20239:42 amRNSForm 8.5 (EPT/RI)
24th Aug 20239:27 amRNSForm 8.5 (EPT/RI) - Yourgene Health PLC
23rd Aug 20239:50 amRNSForm 8.5 (EPT/RI)
23rd Aug 20239:24 amRNSForm 8.3 - Yourgene Health PLC
22nd Aug 20231:25 pmRNSHolding(s) in Company
22nd Aug 20239:01 amRNSForm 8.5 (EPT/RI)
21st Aug 20235:29 pmRNSForm 8.3 - Yourgene Health plc
21st Aug 20232:12 pmRNSForm 8.3 - Yourgene Health plc
21st Aug 202311:03 amRNSForm 8.5 (EPT/RI) - Yourgene Health PLC
21st Aug 20237:02 amRNSForm 8.3 - Yourgene Health PLC
18th Aug 20233:09 pmRNSForm 8.3 - Yourgene Health plc
18th Aug 20231:28 pmRNSForm 8.5 (EPT/RI)
17th Aug 20235:03 pmRNSResult of Court Meeting and General Meeting
17th Aug 202310:13 amRNSForm 8.5 (EPT/RI)
16th Aug 20239:40 amRNSForm 8.5 (EPT/RI)
15th Aug 20234:41 pmRNSForm 8.5 (EPT/RI) Replacement
15th Aug 202312:00 pmRNSForm 8.5 (EPT/RI)
14th Aug 202310:16 amRNSForm 8.5 (EPT/RI)
14th Aug 20239:20 amRNSForm 8.3 - Yourgene Health PLC
11th Aug 20231:12 pmRNSForm 8.3 - Yourgene Health plc
11th Aug 202310:10 amRNSForm 8.5 (EPT/RI)
10th Aug 202311:59 amRNSForm 8.5 (EPT/RI)
9th Aug 202310:12 amRNSForm 8.5 (EPT/RI)
8th Aug 20231:57 pmRNSForm 8.3 - Yourgene Health plc
8th Aug 202311:43 amRNSForm 8.5 (EPT/RI)
7th Aug 20231:57 pmRNSForm 8.3 - Yourgene Health plc
7th Aug 202311:56 amRNSForm 8.5 (EPT/RI)
4th Aug 20231:35 pmRNSForm 8.3 - Yourgene Health plc
4th Aug 202310:54 amRNSForm 8.5 (EPT/RI)
4th Aug 202310:47 amRNSForm 8.3 - Yourgene Health PLC
3rd Aug 202310:04 amRNSForm 8.5 (EPT/RI)
3rd Aug 20239:51 amRNSForm 8.3 - Yourgene Health PLC
3rd Aug 20239:19 amRNSForm 8.3 - YOURGENE HEALTH PLC
2nd Aug 20232:02 pmRNSForm 8.3 - Yourgene Health plc
2nd Aug 202310:21 amRNSForm 8.5 (EPT/RI)
1st Aug 20235:30 pmRNSForm 8.5 (EPT/RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.